Hantavirus pulmonary syndrome

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
월요일, 6월 12, 2023
Vaccine, Yellow fever, Human, Ebola, Completeness, Prevalence, Rift Valley fever, Infection, Fever, Hantavirus pulmonary syndrome, Key, Viral hemorrhagic fever, Hygiene, VHF, Government, Blood, HPS, Animal, Lymphocytic choriomeningitis, Lassa fever, Research, Study, Disease, Retail, Online shopping, Video game, RVSV-ZEBOV vaccine, Medication, Others, Growth, Ribavirin, Forecast

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
월요일, 6월 12, 2023
Vaccine, Yellow fever, Human, Ebola, Completeness, Prevalence, Rift Valley fever, Infection, Fever, Hantavirus pulmonary syndrome, Key, Viral hemorrhagic fever, Hygiene, VHF, Government, Blood, HPS, Animal, Lymphocytic choriomeningitis, Lassa fever, Research, Study, Disease, Retail, Online shopping, Video game, RVSV-ZEBOV vaccine, Medication, Others, Growth, Ribavirin, Forecast

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

EcoClear Products Partners With the Pest Management Association of Texas

Retrieved on: 
화요일, 3월 29, 2022
National Pest Management Association, Population, RATS, Rat-bite fever, Family Dollar, Insecticide, Mouse, PETS, Family, Association, Safety, Hantavirus pulmonary syndrome, GLOBE, Rodenticide, Livestock, Partnership, Trapping, Leptospirosis, Salmonellosis

With pest infestations a serious issue nationwide, EcoClear Products , a company dedicated to providing 100% safe alternatives to harmful rodenticides and insecticides, announces it has expanded its partnership with the National Pest Management Association to its Texas division to help more businesses with this serious issue.

Key Points: 
  • With pest infestations a serious issue nationwide, EcoClear Products , a company dedicated to providing 100% safe alternatives to harmful rodenticides and insecticides, announces it has expanded its partnership with the National Pest Management Association to its Texas division to help more businesses with this serious issue.
  • Through this new partnership,EcoClear Products will leverage its offerings with the Texas Pest Management Association to help control the increasing rodent population.
  • "At EcoClear Products, we're passionate about providing consumers and professionals with alternatives to harmful rodenticides and insecticides to address this problem,"said Christopher Stidd, founder of EcoClear Products.
  • EcoClear Products is dedicated to innovating effective pest and rodent control products that are safe for use around people, pets, livestock, and wildlife.

DGAP-News: Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections

Retrieved on: 
월요일, 1월 10, 2022
Safety, CDC, Viral hemorrhagic fever, RSV, RNP, Risk, Macrophage inflammatory protein, Severe acute respiratory syndrome coronavirus 2, Viral load, Death, Orthohantavirus, CSO, Patient, Orthornavirae, ODD, Chemokine, Gene expression, Category, Orphan drug, Hantavirus pulmonary syndrome, RNA, III, Food, Patent, ECDC, Therapy, Degenerative disease, Cell, Company, Cytoplasm, Cytokine, Human, Vaccine, CEO, COVID-19, FDA, Disease, Gesellschaft mit beschränkter Haftung, Orphan, Fatality, Hantavirus hemorrhagic fever with renal syndrome, HPS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MEK, Pharmaceutical industry, HFRS, zapnometinib's mode of action with dual effect, Atriva Therapeutics GmbH, ZAPNOMETINIB'S MODE OF ACTION WITH DUAL EFFECT, ATRIVA THERAPEUTICS GMBH

"Antiviral efficacy of zapnometinib against hantavirus has been previously proven in vitro in an academic collaboration.

Key Points: 
  • "Antiviral efficacy of zapnometinib against hantavirus has been previously proven in vitro in an academic collaboration.
  • Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, commented: "The Orphan Drug Designation we received for our lead drug candidate zapnometinib is an important milestone towards addressing the urgent needs of patients infected with hantavirus.
  • [1]
    The FDA may grant Orphan Drug Designation (ODD) to support the development and evaluation of new treatments for rare diseases.
  • [11]
    The Atriva lead product zapnometinib (ATR-002) is developed specifically to treat diseases such as influenza and COVID-19, caused by RNA viruses.